Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years
Alveolar soft part sarcoma (ASPS) is a rare malignant tumor that generally occurs in adolescents and young adults. It progresses slowly, but lung and brain metastases often occur in the early phase of the clinical course, and chemotherapy has been reported as not being effective for ASPS. Pazopanib...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2017/3738562 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566146139684864 |
|---|---|
| author | Yoji Shido Yukihiro Matsuyama |
| author_facet | Yoji Shido Yukihiro Matsuyama |
| author_sort | Yoji Shido |
| collection | DOAJ |
| description | Alveolar soft part sarcoma (ASPS) is a rare malignant tumor that generally occurs in adolescents and young adults. It progresses slowly, but lung and brain metastases often occur in the early phase of the clinical course, and chemotherapy has been reported as not being effective for ASPS. Pazopanib is a multitargeted tyrosine kinase inhibitor that has been clinically available from November 2012 in Japan. This is a case report of a patient presented with multiple lung metastases and unresectable primary abdominal ASPS. We initially treated this patient by systemic chemotherapy with combination use of ifosfamide and doxorubicin. Stable disease was observed without any objective response. Then, we finally started to administrate pazopanib 800 mg/day. After 25 months of pazopanib administration, slight tumor reduction and a decrease of enhancement were observed. Objective responses were achieved for both the primary tumor and metastatic lung tumor; however, a newly developed brain metastasis was subsequently identified. Based on this case, pazopanib appears effective against ASPS, except for brain metastases. This case suggests that pazopanib may be useful as a first-line drug against unresectable ASPS and that longitudinal assessment of brain metastasis should be performed in similar cases. |
| format | Article |
| id | doaj-art-8dd28ad223804e06af351f9634175fa5 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-8dd28ad223804e06af351f9634175fa52025-02-03T01:04:57ZengWileyCase Reports in Oncological Medicine2090-67062090-67142017-01-01201710.1155/2017/37385623738562Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three YearsYoji Shido0Yukihiro Matsuyama1Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, JapanDepartment of Orthopaedic Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, JapanAlveolar soft part sarcoma (ASPS) is a rare malignant tumor that generally occurs in adolescents and young adults. It progresses slowly, but lung and brain metastases often occur in the early phase of the clinical course, and chemotherapy has been reported as not being effective for ASPS. Pazopanib is a multitargeted tyrosine kinase inhibitor that has been clinically available from November 2012 in Japan. This is a case report of a patient presented with multiple lung metastases and unresectable primary abdominal ASPS. We initially treated this patient by systemic chemotherapy with combination use of ifosfamide and doxorubicin. Stable disease was observed without any objective response. Then, we finally started to administrate pazopanib 800 mg/day. After 25 months of pazopanib administration, slight tumor reduction and a decrease of enhancement were observed. Objective responses were achieved for both the primary tumor and metastatic lung tumor; however, a newly developed brain metastasis was subsequently identified. Based on this case, pazopanib appears effective against ASPS, except for brain metastases. This case suggests that pazopanib may be useful as a first-line drug against unresectable ASPS and that longitudinal assessment of brain metastasis should be performed in similar cases.http://dx.doi.org/10.1155/2017/3738562 |
| spellingShingle | Yoji Shido Yukihiro Matsuyama Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years Case Reports in Oncological Medicine |
| title | Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years |
| title_full | Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years |
| title_fullStr | Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years |
| title_full_unstemmed | Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years |
| title_short | Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years |
| title_sort | advanced alveolar soft part sarcoma treated with pazopanib over three years |
| url | http://dx.doi.org/10.1155/2017/3738562 |
| work_keys_str_mv | AT yojishido advancedalveolarsoftpartsarcomatreatedwithpazopaniboverthreeyears AT yukihiromatsuyama advancedalveolarsoftpartsarcomatreatedwithpazopaniboverthreeyears |